Opportunity
Federal Register #2026-23692
FDA Draft Product-Specific Drug Guidance Notice
Buyer
Department of Health and Human Services / Food and Drug Administration
Posted
November 20, 2026
Respond By
January 19, 2027
Identifier
2026-23692
The Food and Drug Administration (FDA), part of the Department of Health and Human Services (HHS), announces new and revised draft drug guidance topics; this is not a procurement opportunity. - Buyer / issuing agency: FDA, HHS. No sub-agency or office is identified. - Notice scope: Draft product-specific guidance offers recommendations, including on bioequivalence studies for abbreviated new drug applications (ANDAs). - New guidance topics: aficamten, barium sulfate, berotralstat dihydrochloride, bumetanide, delgocitinib, dihydroergotamine mesylate, ethinyl estradiol with norethindrone acetate, imlunestrant tosylate, lamotrigine, nerandomilast, orforglipron, paltusotine hydrochloride, remibrutinib, sepiapterin, and zongertinib. - Revised guidance topics: albuterol sulfate, azathioprine, betaxolol hydrochloride, bupropion hydrochloride with dextromethorphan hydrobromide, carbinoxamine maleate, conjugated estrogens, gabapentin enacarbil, ixazomib citrate, lanreotide acetate, lenvatinib mesylate, naltrexone, nitroglycerin, pyridostigmine bromide, and trifarotene. - Procurement details: No products or services are being purchased; no vendors, OEMs, quantities, part numbers, or contract value are specified. The notice invites public comments on the draft guidance.
Description
The FDA announces the availability of new and revised draft product-specific guidances for industry. The guidances provide product-specific recommendations, including on designing bioequivalence studies to support abbreviated new drug applications (ANDAs). The notice identifies the active ingredients covered by the draft guidances and invites comments by January 19, 2027, before FDA begins work on final versions.